Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2 Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization

Trial Profile

A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2 Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Therapeutic Use
  • Sponsors Essen Technology (Beijing)
  • Most Recent Events

    • 01 Mar 2017 Results (n=907) of substudy, published in the Catheterization and Cardiovascular Interventions
    • 20 Feb 2013 Planned number of patients changed from 2970 to 2790 as reported by ClinicalTrials.gov.
    • 13 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top